1 Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study

2 First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial

3 Atypical mycobacterial infections of Hickman catheter exit sites

4 Applying Data Warehousing to a Phase III Clinical Trial From the Fondazione Italiana Linfomi Ensures Superior Data Quality and Improved Assessment of Clinical Outcomes

5 Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF

6 Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis

7 Elevated bioactive prolactin levels in systemic lupus erythematosus--association with disease activity

8 INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53

9 Iron metabolism of established human hematopoietic cell lines in vitro

10 Benzoxathiol derivative BOT-4-one suppresses L540 lymphoma cell survival and proliferation via inhibition of JAK3/STAT3 signaling.

11 Human herpesvirus-6 pneumonitis in a patient with follicular lymphoma following immunochemotherapy with rituximab

12 Burkitt Lymphoma of the Duodenum: An Uncommon Phenomenon

13 A Rare Case of Grey Zone Lymphoma Successfully Treated with Brentuximab Vedotin and R-CHP Chemotherapy

14 Human herpesvirus-6 pneumonitis in a patient with follicular lymphoma following immunochemotherapy with rituximab

15 An Unusual Presentation of Pediatric Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma

16 Composite Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and T-Prolymphocytic Leukemia Presenting with Lymphocytosis, Skin Lesions, and Generalized Lymphadenopathy

17 Rare Primary Pulmonary Marginal Zone Lymphoma Presenting with Incidental Pulmonary Nodules

18 Breed prevalence of canine lymphoma in South Africa

19 The prognostic value of tumor-associated macrophages in Non-Hodgkin's Lymphoma: A systematic review and meta-analysis.

20 A genome-wide association study identifies susceptibility loci for primary central nervous system lymphoma at 6p25.3 and 3p22.1: a LOC network study.

21 Author Correction: Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome.

22 Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome.

23 Destitution, treatment adherence and survival of children with Burkitt lymphoma in a twinning programme in Northwest Cameroon.

24 Kaposi Sarcoma in Association With an Extracavitary Primary Effusion Lymphoma Showing Unusual Intravascular Involvement: Report of a Case Harboring a FAM175A Germline Mutation.

25 Primary triple head and neck tumors: Laryngeal squamous cell carcinomas, Kaposi's sarcoma, and non-Hodgkin's lymphoma.

26 Primary triple head and neck tumors: Laryngeal squamous cell carcinomas, Kaposi's sarcoma, and non-Hodgkin's lymphoma

27 Oral non-Hodgkin′s lymphoma as an initial diagnosis in a HIV positive patient

28 Immunophenotype switching in cutaneous T-cell lymphoma: nature or nurture?

29 Perforated gastric diffuse large B-cell lymphoma: A case report and literature review

30 Relaxation and exercise in lymphoma survivors (REIL study): a randomised clinical trial protocol.

31 Progress due to networking structures : Challenges for the Competence Network Malignant Lymphomas in the Era of Precision Medicine

32 Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trial.

33 Home-Based yoga program for the patients suffering from malignant lymphoma during chemotherapy: A feasibility study

34 Plasmablastic lymphoma of bone marrow: Report of a rare case and immunohistochemistry based approach to the diagnosis

35 Pachymeningeal Involvement with Blindness as the Presenting Manifestation of Non-Hodgkin Lymphoma

36 Expression of blood hepatocyte-derived microRNA-122 in canine multicentric lymphoma with hepatic involvement.

37 Evaluation of the Impact of Autologous Hematopoietic Stem Cell Transplantation on the Quality of Life of Older Lymphoma Patients.

38 Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies.

39 STAT6 activation correlates with cerebrospinal fluid IL-4 and IL-10 and poor prognosis in Primary Central Nervous System Lymphoma.

40 Primary Pulmonary Involvement in Mucosa-associated Lymphoid Tissue Lymphoma.

41 [Hodgkin's lymphoma associated with inflammatory bowel disease treated with thiopurines. A case report and review of the literature].

42 Fatty acid beta oxidation enzyme HADHA is a novel potential therapeutic target in malignant lymphoma.

43 CD163 is a predictive biomarker for prognosis of classical Hodgkin's lymphoma in Saudi patients.

44 Die histologischen Typen der lymphomatoiden Papulose - Ein Vorschlag für die Vereinfachung des Buchstabenchaos.

45 Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes.

46 Comparative Effectiveness of Chemotherapy, Rituximab, and Bendamustine in Medicare Beneficiaries With Mantle-Cell Lymphoma.

47 Synchronous Pancreatic Solid Pseudopapillary Neoplasm Masquerading as Extralymphatic Involvement on F-Fluoro-2-deoxy-D-glucose Positron Emission Tomography/Computed Tomography in a Case of Hodgkin's Lymphoma.

48 Long noncoding RNA HAGLROS promotes the process of mantle cell lymphoma by regulating miR-100/ATG5 axis and involving in PI3K/AKT/mTOR signal

49 Diagnosis and management of intramedullary spinal cord lymphoma: A case illustration and review of literature

50 Gastrointestinal lymphoma: the new mimic.

51 Assessment of the Combined Effect of Epstein–Barr Virus and Plasmodium falciparum Infections on Endemic Burkitt Lymphoma Using a Multiplex Serological Approach

52 Primary bone lymphoma of patella: A case report and review of literature.

53 HIV/AIDS-related lymphoma: perspective from a regional cancer center in India.

54 Epstein-Barr Virus Primary Infection Complicated by Hemophagocytic Lymphohistiocytosis and Plasmablastic Lymphoma in a HIV-Negative Patient.

55 Endobronchial Pseudocarcinomatous Hyperplasia Mimicking Squamous Cell Carcinoma Associated with Primary Pulmonary ALK-negative Anaplastic Large Cell Lymphoma.

56 [Expression and Clinical Significance of Serum LRG1 in Patients with Diffuse Large B-Cell Lymphoma before Treatment].

57 Clinicopathological Characterization of Children With B-Cell Non-Hodgkin Lymphoma Over 10 Years at a Tertiary Center in Cape Town, South Africa.

58 Breast implant-associated anaplastic large cell lymphoma and effusions: A review with emphasis on the role of cytopathology.

59 Outpatient rituximab, ifosfamide, etoposide (R-IE) in patients older than 60 years with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for stem cell transplantation.

60 Antitumor effects of rafoxanide in diffuse large B cell lymphoma via the PTEN/PI3K/Akt and JNK/c-Jun pathways.

61 Human herpes virus 8-unrelated primary effusion lymphoma-like lymphoma: report of a rare case and review of the literature.

62 NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death.

63 Low incidence of post-transplant lymphoproliferative disorder after allogeneic stem cell transplantation in patients with lymphoma treated with rituximab.

64 Intravascular Large B-cell Lymphoma Associated with Systemic and Central Nervous System Hemophagocytic Lymphohistiocytosis: A Case Report.

65 The Unsolved Puzzle of c-Rel in B Cell Lymphoma

66 IRF4 translocation status in pediatric follicular and diffuse large B-cell lymphoma patients enrolled in Children's Oncology Group trials.

67 Follicular lymphoma suggested to transform into EBV-negative plasmablastic lymphoma.

68 Correction: Discovery of Entrectinib: A New 3-Aminoindazole as a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor (Journal of Medicinal Chemistry (2016) 59: 7 (3392-3408) DOI: 10.1021/acs.jmedchem.6b00064)

69 Elephantiasis nostras verrucosa: an atypical presentation following intrapelvic lymphoma.

70 Coarse-to-Fine Adversarial Networks and Zone-based Uncertainty Analysis for NK/T-cell Lymphoma Segmentation in CT/PET images.

71 Challenges and limitations of primary diagnosis of T-cell and NK/T-cell lymphoma in bone marrow biopsy.

72 Prognosis estimation under the light of metabolic tumor parameters on initial FDG-PET/CT in patients with primary extranodal lymphoma

73 Occipital Hypometabolism on FDG PET/CT Scan in a Child with Hodgkin’s Lymphoma

74 Biological Features and Prognostic Impact of Bone Marrow Infiltration in Patients with Diffuse Large B-Cell Lymphoma.

75 Inflammatory Infiltrate and Angiogenesis in Mantle Cell Lymphoma.

76 Involvement of p53 acetylation in growth suppression of Cutaneous T-cell lymphomas induced by HDAC inhibition.

77 Synthesizing efficacious genistein in conjugation with superparamagnetic FeO decorated with bio-compatible carboxymethylated chitosan against acute leukemia lymphoma.

78 [The Application Value of True Whole-body PET/CT Scanning Protocol in Patients of Extranodal NK/T Cell Lymphoma].

79 Artificial Intelligence Analysis of Gene Expression Data Predicted the Prognosis of Patients with Diffuse Large B-Cell Lymphoma.

80 Impact of delaying initiation of anaplastic lymphoma kinase inhibitor treatment on survival in patients with advanced non-small-cell lung cancer.

81 Clinicopathological and genetic features of limited-stage diffuse large B-cell lymphoma with late relapse: targeted sequencing analysis of gene alterations in the initial and late relapsed tumors.

82 Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group.

83 Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK-positive anaplastic large-cell lymphoma refractory to chemotherapy and brentuximab vedotin.

84 Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R) vs. rituximab + placebo in relapsed/refractory indolent non-Hodgkin lymphoma.

85 A comparison of clinical staging using the Lugano versus Ann Arbor classifications in Japanese patients with Hodgkin lymphoma.

86 DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 study.

87 Association of CD204 macrophages with poor outcomes of malignant lymphomas not in remission treated by allogeneic HCT.

88 Retreatment with brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study.

89 Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review

90 Web-Based Self-Management for Patients With Lymphoma: Assessment of the Reach of Intervention of a Randomized Controlled Trial.

91 Non-Nodal CD5-Negative Mantle Cell Lymphoma with Secondary TP53 Deletion.

92 High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease.

93 Monoclonal antibody therapy of murine lymphoma: enhanced efficacy by concurrent administration of interleukin 2 or lymphokine-activated killer cells.

94 Author Correction: Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma (Nature Medicine, (2020), 26, 2, (270-280), 10.1038/s41591-019-0737-3)

95 NLP Hodgkin lymphoma: can we get away with less?

96 Genes regulating the B cell receptor pathway are recurrently mutated in primary central nervous system lymphoma

97 Corneal Epithelial Toxicity after Intravitreal Methotrexate Injection for Vitreoretinal Lymphoma: Clinical and In Vitro Studies

98 Outcome of Radiotherapy for Gastric Mucosa-Associated Lymphoid Tissue Lymphoma Refractory to Helicobacter Pylori Eradication Therapy

99 Evaluation of the circulating and splenic lymphocyte subpopulations in patients with non-hodgkin lymphomas and Hodgkin's disease using monoclonal antibodies

100 Infection risk and cancer chemotherapy: the impact of the chemotherapeutic regimen in patients with lymphoma and solid tissue malignancies.

101 Parkinsonian syndrome and central nervous system lymphoma involving the substantia nigra

Keyword Connections

Journals

Research Groups

Bibliographies